Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant trastuzumab, docetaxel, and pertuzumab study in HER2-positive breast cancer
2007-001105-13Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Trastuzumab + docetaxel, Trastuzumab + docetaxel + pertuzumab and Trastuzumab + pertuzumab (3 arms). Primary endpoint: Pathological complete response rate in the breast. Started Aug 2007; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-001105-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001105-13.